AU2022267325A1 - Methods for treating and monitoring parkinson's disease - Google Patents

Methods for treating and monitoring parkinson's disease Download PDF

Info

Publication number
AU2022267325A1
AU2022267325A1 AU2022267325A AU2022267325A AU2022267325A1 AU 2022267325 A1 AU2022267325 A1 AU 2022267325A1 AU 2022267325 A AU2022267325 A AU 2022267325A AU 2022267325 A AU2022267325 A AU 2022267325A AU 2022267325 A1 AU2022267325 A1 AU 2022267325A1
Authority
AU
Australia
Prior art keywords
compound
subject
lrrk2
disease
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022267325A
Other languages
English (en)
Inventor
Vinay M. DARYANI
Sarah HUNTWORK-RODRIGUEZ
Danna L. JENNINGS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of AU2022267325A1 publication Critical patent/AU2022267325A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2022267325A 2021-04-30 2022-04-29 Methods for treating and monitoring parkinson's disease Pending AU2022267325A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182207P 2021-04-30 2021-04-30
US63/182,207 2021-04-30
PCT/US2022/026898 WO2022232487A1 (en) 2021-04-30 2022-04-29 Methods for treating and monitoring parkinson's disease

Publications (1)

Publication Number Publication Date
AU2022267325A1 true AU2022267325A1 (en) 2023-11-16

Family

ID=83847331

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022267325A Pending AU2022267325A1 (en) 2021-04-30 2022-04-29 Methods for treating and monitoring parkinson's disease

Country Status (9)

Country Link
US (1) US20240207266A1 (https=)
EP (1) EP4329763A4 (https=)
JP (1) JP2024515885A (https=)
CN (1) CN117769422A (https=)
AU (1) AU2022267325A1 (https=)
CA (1) CA3217230A1 (https=)
MX (1) MX2023012851A (https=)
TW (1) TW202308635A (https=)
WO (1) WO2022232487A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051214A1 (zh) * 2023-09-07 2025-03-13 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
CN121226329A (zh) * 2024-06-28 2025-12-30 成都康弘药业集团股份有限公司 一种治疗或预防lrrk2介导的疾病的化合物
CN119119035B (zh) * 2024-08-30 2025-11-04 中山大学 一种ripk1激酶靶点抑制剂及其制备方法与应用
CN118878521B (zh) * 2024-09-26 2025-02-14 苏州美诺医药科技有限公司 一种lrrk2抑制剂的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102091895B1 (ko) * 2012-05-03 2020-04-14 제넨테크, 인크. 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
SMT202100699T1 (it) * 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi

Also Published As

Publication number Publication date
EP4329763A1 (en) 2024-03-06
CA3217230A1 (en) 2022-11-03
TW202308635A (zh) 2023-03-01
EP4329763A4 (en) 2025-03-05
MX2023012851A (es) 2024-03-19
WO2022232487A1 (en) 2022-11-03
US20240207266A1 (en) 2024-06-27
CN117769422A (zh) 2024-03-26
JP2024515885A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
US20240207266A1 (en) Methods for treating and monitoring parkinson's disease
Balu et al. Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease
Rodgers et al. Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst β-blocking drugs in rat
Haider et al. Translational molecular imaging and drug development in Parkinson’s disease
Bergin et al. Altered plasma arginine metabolome precedes behavioural and brain arginine metabolomic profile changes in the APPswe/PS1ΔE9 mouse model of Alzheimer’s disease
Mollá et al. Modulators of neuroinflammation have a beneficial effect in a Lafora disease mouse model
Vitte et al. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease
ES2870851T3 (es) Método para detectar enfermedades musculares degenerativas y método para determinar la eficacia terapéutica sobre las enfermedades
WO2019089988A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
Tan et al. A multifunctional bis-(−)-nor-meptazinol-oxalamide hybrid with metal-chelating property ameliorates Cu (II)-induced spatial learning and memory deficits via preventing neuroinflammation and oxido-nitrosative stress in mice
US20250177351A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
Kim et al. A naturally occurring variant of SHLP2 is a protective factor in Parkinson’s disease
Zhao et al. Branched-chain amino acids contribute to diabetic kidney disease progression via PKM2-mediated podocyte metabolic reprogramming and apoptosis
US20200046693A1 (en) Compositions and methods for the treatment of zellweger spectrum disorder
Yan et al. Dysregulation of iron homeostasis and methamphetamine reward behaviors in Clk1-deficient mice
van Harskamp et al. Development and validation of a new gas chromatography–tandem mass spectrometry method for the measurement of enrichment of Glyoxylate metabolism Analytes in Hyperoxaluria patients using a stable isotope procedure
Liu et al. Absorption, tissue disposition, and excretion of fasudil hydrochloride, a RHO kinase inhibitor, in rats and dogs
Hényková et al. Quantitative Determination of Endogenous Tetrahydroisoquinolines, Potential Parkinson’s Disease Biomarkers, in Mammals
JP2025023272A (ja) 脳脊髄液に含まれるＨｅｘ４，ｌｙｓｏ－ＧＭ１，Ｆｕｃ－ＧｌｃＮＡｃ－Ａｓｎ，及びｌｙｓｏ－ｓｕｌｆａｔｉｄｅの定量法
Sang et al. Thiamine pyrophosphokinase-1 deficiency in neurons drives Alzheimer’s multiple pathophysiological alterations
Henning Determination of relationship between dolutegravir and trace amine profile, using advanced liquid chromatography tandem mass spectrometry analysis of various tissues
IL323026A (en) Treatment of Parkinson's disease in a patient using a glucocerebrosidase activator
Smith Development and Validation of Toxicological Methods for Cognitive Stimulants in Traditional and Alternative Matrices
NAZ et al. DEVELOPMENT OF QUANTITATIVE METHOD OF TULOBUTEROL HYDROCHLORIDE IN RAT PLASMA: VALIDATION AND APPLICATION TO PRECLINICAL PHARMACOKINETICS
Hagos The Role of Membrane Transporters in Traumatic Brain Injury: Interventional and Genetic Investigations